Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (316)	6/28/2007 10:32:32 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 360

Gene Logic Enters Into Agreement with Lundbeck phx.corporate-ir.net; Charles L. Dimmler, III, Gene Logic CEO commented, "Lundbeck has an outstanding reputation as a developer of therapeutics for central nervous system disorders. We are pleased to be partnering with an innovative organization such as Lundbeck. With six current pharmaceutical company drug repositioning partnerships, our approach is establishing Gene Logic as the industry's drug repositioning leader." In a separate agreement unrelated to its drug repositioning partnerships, Gene Logic announced that it expects to realize approximately $2.5 million in fees from Lundbeck for a license to certain technology rights controlled by Gene Logic. The revenue will be recognized over the coming year.